Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma
FAK inhibitors can enhance the sensitivity of HCC to anti-PD-1 therapy by inhibiting angiogenesis and fibrosis and promoting CD8<sup>+</sup> T cell infiltration. This effect exceeds the efficacy of the current first-line treatment, highlighting FAK inhibition as a novel and promising therapeutic strategy for HCC.
Authors
- Ruirui Kong (ORCID: https://orcid.org/0000-0002-3886-4467)
- Peng Cui (ORCID: https://orcid.org/0000-0002-4566-6223)
- Fangyanni Wang
- Ning Zhang (ORCID: https://orcid.org/0000-0001-7182-0100)
- Xinyu Liu (ORCID: https://orcid.org/0000-0002-2388-844X)
- Ziyi Zheng
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University First Hospital (CN)
- Yunnan Investment Group (China) (CN)
Publication Details
- Journal
- Journal of Translational Internal Medicine
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1515/jtim-2025-0051
- Primary Topic
- Cell Adhesion Molecules Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00